CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples